KORU Medical (KRMD) Q2 2026 earnings review
Profitability Achieved, But Oncology Strategy Pivot Raises Questions
KORU hit a major milestone with its first GAAP profitable quarter, posting a Net Income of $0.25M on the back of 18% revenue growth and a breakout in Gross Margin to 65.1%. However, the long-term strategic narrative took a sudden and unexpected turn. Management withdrew its highly anticipated Phesgo 510(k) application—previously hyped as a major entry into a $120M oncology TAM—and warned of moderating international growth in H2. As a result, the top end of FY26 revenue guidance was cut, partially overshadowing the excellent bottom-line execution.
🐂 Bull Case
Gross margin expanded to 65.1%, proving the company can achieve operating leverage. The newly signed multi-year supply agreement provides a clear runway for long-term structural margin expansion.
The core domestic business continues to consistently outpace the underlying SCIg market, growing a stable 12.4% in Q2 driven by new patient starts.
🐻 Bear Case
Withdrawing the Phesgo 510(k) damages credibility regarding the non-Ig pipeline execution. KORU is now pivoting to 'alternative higher volume molecules,' which resets the clock on their oncology market entry.
After quarters of explosive growth driven by EU pre-filled syringe (PFS) conversions, management explicitly expects international core growth to 'moderate' due to regional launch dynamics.
⚖️ Verdict: ⚪
Neutral. The financial print is excellent, validating the path to sustained profitability. However, the unexpected withdrawal of a key oncology asset and the lowered top-end revenue guidance introduce new execution risks to the growth story.
Key Themes
Phesgo 510(k) Withdrawal Resets Oncology Timeline
Reversing. KORU abruptly withdrew its 510(k) application for the FreedomEDGE with Phesgo. After heavily promoting the oncology TAM expansion (projected to grow to $120M+) in prior quarters, management is now 'strategically shifting' to alternative molecules. This is a material setback that completely contradicts the previously optimistic pipeline narrative.
Gross Margin Breakout
Accelerating. Gross margin jumped to 65.1% from 63.5% a year ago, driven by lower manufacturing costs and higher average selling prices. This successfully offsets the tariff pressures discussed extensively in FY25. Furthermore, management signed a new multi-year supply agreement specifically to 'support long-term gross margin expansion,' solidifying this as a structural driver rather than a one-off beat.
International Growth Set to Moderate
Decelerating. International Core revenue surged 59.1% YoY to $3.5M in Q2, driven by distributor purchases for EU pre-filled syringe (PFS) conversions. However, CEO Adam Kalbermatten explicitly warned that international core growth will 'moderate' in the second half due to regional launch dynamics. This explains the company's decision to narrow top-line guidance despite a strong Q2.
Connected Monitoring Technology Acquisition
KORU made a strategic acquisition of a connected monitoring technology asset. This represents a significant shift toward digital health, aiming to enhance the platform with real-time data insights on patient usage. If successfully integrated, this could provide a massive competitive moat and improve patient adherence data for pharma partners.
Other KPIs
Stable. Grew 12.4% YoY, heavily driven by new patient starts and consistent market share gains within the underlying SCIg market. This segment remains the predictable bedrock of the business, offsetting international volatility.
Reversing. Dropped 35.0% YoY, a sharp turnaround from the 166% growth seen in 26Q1. Management attributed this to lower clinical trial product revenues related to customer order timing, highlighting the inherent lumpiness of this segment.
Accelerating. Dramatically improved from $0.34M in the prior year period. The operating leverage is working—revenue grew 18% while total operating expenses only increased 6.3%.
Guidance
Decelerating. The company narrowed its guidance range, effectively chopping the top end from the prior $50.0M ceiling. This implies a growth range of 15% - 18%, down from the previously guided 15% - 22%, reflecting the expected moderation in European PFS conversions.
Accelerating. Raised from the prior guidance of 61% - 63%. The Q2 performance (65.1%) and the newly inked multi-year supply agreement give management confidence to lift the floor and ceiling of their profitability targets.
Decelerating. This was updated (implicitly lowered from prior historical expectations) specifically to account for the cash outflow used in the technology acquisition, though KORU ended Q2 with $8.3M.
Key Questions
Phesgo 510(k) Specifics
What were the specific FDA feedback points or strategic realizations that led to the withdrawal of the Phesgo 510(k)? How far out does this push our timeline for entering the oncology market?
Connected Technology Integration
Regarding the newly acquired connected monitoring asset: what is the timeline for commercial integration, and how do we plan to monetize these real-time data insights with our pharma partners?
International Moderation
Can you quantify the expected H2 'moderation' in international core growth? Is this purely a timing issue with tender/reimbursement dynamics, or are we seeing competitive pushback in the EU?